MEK

ADC Related

ADC Antibody ADC Cytotoxin ADC Linker ADCs Drug-Linker Conjugates for ADC
Angiogenesis

5-alpha Reductase ALK Bcr-Abl BTK EGFR FAK FLT3 HER-2 HIF Src Syk VDA VEGFR
Anti-infection

Antibiotic Arenavirus Bacterial CMV EBV Enterovirus Filovirus Fungal Gli HBV HCV HCV Protease HIV HSV Influenza Virus Parasite RABV Reverse Transcriptase RSV SARS-CoV TMV Virus Protease
Apoptosis

Apoptosis ASK Bcl-2 Caspase c-Myc c-RET Cytohesin DAPK Ferroptosis FKBP IAP Mdm2 p53 PD-1 PD-L1 PERK PKD Ras RIP kinase ROS Survivin Thymidylate Synthase TNF Receptor TNFa TRADD
Autophagy

Autophagy LRRK2 Mitophagy OGA ULK
Cell Cycle

Antifolate APC Aurora Kinase BMI-1 CDK Chk c-Myc Eukaryotic Initiation Factor G-quadruplex HDAC HSP Kinesin LIMK Mad2 Microtubule(Tubulin) Mps1 Nucleoside Antimetabolite/Analog Nur77 p21 PAK PERK PFKFB PLK PPAR Ras Rho ROCK SRPK TOPK Topoisomerase Wee1
Cytoskeletal Signaling

Arp2 3 Complex Bcr-Abl Cardiac Myosin Dynamin Gap Junction Protein HSP Integrin Kinesin Microtubule Associated MLCK Myosin PAK TACC3 Wntbeta-catenin
DNA Damage

ATM(ATR) CRISPR(Cas9) DNA alkylator DNA Stain DNA(RNA) Synthesis GAK HDAC HSP Nucleoside Antimetabolite(Analog) OGG1 p97 PARG PARP RAD51 RNR Sirtuin SMN Telomerase Topoisomerase
Endocrinology & Hormones

5-alpha Reductase ACE Adrenergic Receptor Androgen Receptor Aromatase Estrogenprogestogen Receptor Glucocorticoid Receptor GPR Mineralocorticoid Receptor RAAS THR TSH Receptor
Epigenetics

AMPK Aurora Kinase DNA Methyltransferase Epigenetic Reader Domain EZH1 2 HDAC HIF Histone Acetyltransferase Histone Demethylase Histone Methyltransferase JAK MAT MicroRNA MLL Pim PKC Protein Arginine Deiminase Sirtuin Small Interfering RNA (siRNA) SMYD

+MORE

MEK

MEK (Mitogen-activated protein kinase kinase, MAPKK) is a kinase enzyme which phosphorylates mitogen-activated protein kinases (MAPKs).The downstream transcription factors that control responses like stress signaling, pathogen response, and hormone signaling are phosphorylated as a result of the activated MAPK.

The final protein in the cascade, a MAPK (ERK, p38, or JNK), is activated by the MAPKKK by phosphorylating a serine or threonine residue on a MAPKK. Mitogen-activated protein kinase kinase 3 (MKK3), MKK6, and occasionally MKK4 are primarily responsible for activating the p38 MAPK. Two upstream MAP2Ks, MKK4 and MKK7, control the JNK. Raf and Ras are activated by the highly homologous kinases MEK1 and MEK2, which then activate ERK mitogen-activated protein kinases.

MEK related products

Cat No.	Product Name	CAS No.	Product Description
V74094	(R)-PD 0325901CL	1003216-77-0	(R)-PD 0325901CL is an isomer of PD 0325901CL.
V3182	APS-2-79	2002381-25-9	APS-2-79 (APS-279) is a potent antagonist of MAPK (mitogen-activated protein kinase) with antitumor activity.
V2664	APS-2-79 HCl	2002381-31-7	APS-2-79 HCl (APS279 HCl; APS-279), the hydrochloride salt of APS-2-79, is an antagonist of MAPK (mitogen-activated protein kinase) with anticancer effects.
V129573	Atebimetinib	2669009-92-9	Atebimetinib is a novel oral dual MEK inhibitor with anti-pancreatic cancer activity.
V3658	Avutometinib (Ro 5126766)	946128-88-7	Avutometinib (also known as Ro-5126766; CH5126766) is a novel, potent, first-in-class dual inhibitor of MEK/RAFmitogen-activated protein kinases (MAPKs) with anticancer activity.
V0458	AZD8330 (ARRY704; ARRY424704)	869357-68-6	AZD8330 (AZD-8330; ARRY-704; ARRY-424704) is an orally bioactive and non-ATP competitive (Allosteric) MEK 1/2 inhibitor with potential anticancer activity.
V0457	BIX 02188	334949-59-6	BIX02188 (BIX-02188), an indolinone analog, is a novel, highly potent and selective MEK5 inhibitor with the potential to relieve neuropathic pain.
V0450	BIX 02189	1094614-85-3	BIX02189 is a novel, potent andselective inhibitor of MEK5 with important biological activity.
V33372	BIX02189	1265916-41-3	BIX02189 is a novel, potent and selective MEK5 inhibitor with an IC50 of 1.5 nM, also inhibits ERK5 catalytic activity with an IC50 of 59 nM.
V131689	CI-1040 hydrochloride		CI-1040 hydrochloride is an orally effective and highly specific MEK inhibitor with an IC50 of 17 nM for MEK1.
V97312	DS03090629		DS03090629 is an orally available MEK inhibitor that inhibits MEK activity in an ATP-competitive manner.
V135132	Envometinib	2952542-22-0	Envometinib is a dual MEK inhibitor whose mechanism of action is through deep circulating inhibition (DCI).
V136447	G-963	1009330-74-8	G-963 is an allosteric inhibitor of mitogen-activated protein kinase kinase (MEK) with an IC50 value of 0.012 μM for MEK1.
V0451	GDC-0623 (G-868)	1168091-68-6	GDC-0623 (G868) is a novel, potent, orally bioactive, selective and non-ATP-competitive (allosteric) inhibitor of MEK1 with potential anticancer activity.
V74088	GSK1790627	871701-87-0	GSK1790627 is the N-deacetylated metabolite of trametinib.
V4731	GW284543	790186-68-4	GW284543 (also known as GW-284543; UNC10225170; UNC-10225170) is a novel, potent and selectiveMEK5inhibitor with potential usefulness in cancer treatment.
V116080	L-783277	791807-02-8	L-783277 (compound 4) is a MEK inhibitor (IC50 = 4 nM).
V93759	Luvometinib	2739690-43-6	Luvometinib is a mitogen-activated protein kinase (MEK) inhibitor with antitumor activity.
V118781	Luvometinib-d		Luvometinib-d is the deuterated form of Luvometinib.
V116702	MAP2K1 L115P Recombinant Human Active Protein Kinase		MAP2K1 (also known as MEK1) is located downstream of the RAF family, and its activation can lead to the activation of ERK1/2.